Skip to main content
  • Immunotherapy
    in Actions
    The new wave of immunotherapy antibodies in cancers and rare haematological diseases
  • ElsaLys Biotech
    A clinical stage immuno-oncology company that designs and develops
    a new generation of therapeutic antibodies

Welcome to ElsaLys Biotech

ELSALYS BIOTECH is an immuno-oncology company which designs and develops a new generation of therapeutic antibodies targeting tumors and their immune and/or vascular microenvironment.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.

Today ELSALYS BIOTECH is conducting 3 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.

The company is acting today in 3 main medical fields :

New Updates

Discover our latest news regarding our pipeline, our partnerships and more

Thu, 05/07/2020 - 10:30

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

Thu, 01/09/2020 - 13:00
  • The French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) so-call


Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.